Will psilocybin lose its magic in the clinical setting? Dr Caroline Hayes, NHS

Event details

Drug Science Society Lecture

Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community, however, there are a number of potential pitfalls that will need to be addressed if Psilocybin is to become a licensed treatment for depression. This talk will look at a patient case study from the recent phase IIb Compass Pathways trial looking at Psilocybin for treatment-resistant depression that ran in Newcastle, and consider a number of ethical issues in psychedelic research.

Dr Caroline Hayes is a doctor working in the NHS on the core psychiatry training programme. She was a sub-investigator on the phase IIb Psilocybin for treatment resistant depression trial run by Compass Pathways, however, no longer participates in psychedelic research due to ethical concerns.

Partners